Cisplatin Resistance in Cervical Cancer Cell Lines
Author Information
Author(s): K.J. Mellish, L.R. Kelland, K.R. Harrap
Primary Institution: The Institute of Cancer Research
Hypothesis
The study investigates the chemosensitivity of cervical squamous cell carcinoma cell lines to platinum drugs and the mechanisms of acquired resistance.
Conclusion
The study found that the cervical cancer cell lines exhibited intrinsic resistance to cisplatin, with one line showing exceptional sensitivity to a novel platinum compound, JM216.
Supporting Evidence
- All five cervical cancer cell lines were found to be relatively resistant to cisplatin and other platinum drugs.
- HX/156 was exceptionally sensitive to JM216, a novel platinum compound.
- Acquired resistance was observed in HX/155, which showed reduced intracellular drug accumulation.
- Glutathione levels were elevated in the resistant cell line HX/155cisR, suggesting a role in drug resistance.
- Intracellular platinum accumulation was significantly lower in the resistant variant compared to the parent line.
Takeaway
Researchers looked at how some cervical cancer cells resist a common drug called cisplatin and found that one type of cell was very sensitive to a new drug instead.
Methodology
The study used five human cervical squamous cell carcinoma cell lines to assess their sensitivity to various platinum-based drugs through cytotoxicity assays.
Limitations
The study primarily focused on in vitro models, which may not fully represent in vivo conditions.
Participant Demographics
All cell lines were derived from previously untreated patients.
Statistical Information
Statistical Significance
p>0.05
Want to read the original?
Access the complete publication on the publisher's website